Drugmakers aim for Commercialization of Acne Vulgaris Drugs

San Francisco, California, April 26, 2018: The rising prevalence of acne vulgaris as skin diseases in worldwide population, especially among late adolescents, combined with substantial burden disease has on patients is a key factor driving the demand for treatments. The focus on successful management of the disease by a combination of topical and systemic drugs helps in expanding the available therapeutic options, thereby accentuating the market. A new report penned by TMR Research, titled, “Acne Vulgaris Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”, offers insights into such trends and more and evaluates their impact on the growth dynamics over the forecast period of 2017 to 2025.

The market is significantly benefitting from the rising demand for novel therapeutics that can target a wide range of bacterial agents and have anti-inflammatory effect on the acne lesions. In this regard, relentless research in recent years to develop targeted therapeutic modalities have expanded the treatment regime for the disease.

The growing affordability of acne vulgaris treatments in global patient population is a notable factor accentuating the market. The advent of comprehensive treatment such as gels that can target multiple pathogenic factors for acne vulgaris and are helpful in reducing painful lesions is boosting the market.

Get Sample Copy of this Report @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=25

Several pharmaceutical companies are holding back on spending large sums in research and development of therapeutics for acne vulgaris owing to uncertain profits. This may act as a notable constraint in the growth of the market. Nevertheless, a growing number of clinical trials nearing completion will pave way for commercialization of acne vulgaris treatments, thus opening new revenue streams for market players in the coming years.

Prominent players operating in the acne vulgaris market include Valeant Pharmaceuticals International, Inc., Sol-Gel Technologies Ltd., Sol-Gel Technologies Ltd., Hygeia Therapeutics, Inc., Galderma S.A., Photocure ASA, GlaxoSmithKline plc, Ausio Pharmaceuticals, LLC, and AndroScience Corporation.

Acne Vulgaris Market : Outlook by Product Overview, Application and Regions 2025

Global Acne Vulgaris Market: Snapshot

Acne vulgaris-one of the commonest skin disorders-has a multifactorial pathogenesis and is found mainly among adolescents. The pathogenetic mechanism usually consists of four key factors: increased sebum productions, follicular epidermal hyperproliferation, the colonization of bacteria Propionibacterium acnes (P. acne), and effects of inflammation. Successful management of the disease requires a better understanding of various pathogenetic factors and identifying the etiology of the acne in patients. Recent researches in targeted therapeutic modalities have given rise to a host of treatments that meet the specific expectations of the patients and provide enhanced tolerability as well. New treatment options focus on a permutation and combination of anti-acne agents, which are available in the market in varied compositions and formulations.

A vast assortment of topical and systemic drugs available in the market is set to expand therapeutic options for a greater number of patients depending on the stage and symptoms of the disease. Some of the prominent therapies recommended for treating acne vulgaris are: use of topical retinoid, combination therapy, hormonal therapies, antibiotics, and oral isotretinoin.

Request Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=25

Benzoyl peroxide and topical retinoids are the most widespread treatments preferred by dermatologists. Available in different formulations such as lotions, washes, gels, and creams, they can target a wide spectrum of bacterial agents in cases of mild-to-moderate acne vulgaris and have significant anti-inflammatory effects. The efficacy of retinoids have already been proven for over three decades. Dermatologists prefer this as the first-line of treatment for mild-to-moderate noninflammatory and inflammatory acne lesions. Globally, the most intensely researched topical retinoids for the treatment of acne vulgaris are adapalene and tretinoin. A host of topical antibiotics formulations are helpful in inhibiting the growth of commensal bacteria P. acne and reducing inflammation. Most common topic antibiotics available are clarithromycin, azithromycin, and nadifloxacin; however, lack of clinical studies restrain their adoption in various emerging markets.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=25

Global Acne Vulgaris Market: Brief Account 

Acne vulgaris is a chronic and most widespread disease of the sebaceous follicles of the human skin. This basically affects the pilosebaceous units which are present in the skin of the chest, back, and face. Many patients elect medical treatment and care as they are mostly concerned about their appearance. Nevertheless, several patients opt for acne vulgaris treatment because of painful and scarring nodules. This type of disease basically begins at puberty owing to an increase in the androgen levels that eventually triggers a rise in the production of sebum from the skins’ sebaceous glands. This disease is generally characterized through morphological structures including nodules, comedones, and pustules/papules. The disease is eventually treated in terms of acne, the distribution type, severity, and the therapeutics can thus be targeted on the basis of various pathogenic components present. In order to treat the skin disease properly, combination therapy is employed.

The market intelligence report is a comprehensive review of the growth trail in terms of current, historical, and future scenarios of the global acne vulgaris market. It offers an evaluation of the dynamics that are expected to impact the development of the market and the chief trends have also been specified in the research study. The research study also offers a broad lookout on the competitive landscape of the market through Porter’s five forces analysis. The research publication provides references of mergers and acquisitions, the research and development activities, details on licensing and collaborations. The report probes into the strategies related to marketing, shares, and product portfolio of the key participants operating in the global acne vulgaris market.

Read Comprehensive Overview of Report@ https://www.tmrresearch.com/acne-vulgaris-market

Global Acne Vulgaris Market: Trends and Prospects

Main driving aspects for the growth of the acne vulgaris market comprise high occurrence of acne vulgaris, growing incidences of several skin infections, growing demand for innovative therapeutics, and rising awareness and affordability among people worldwide. Acne vulgaris is extremely predominant in many parts of the world. Currently, mounting concerns and awareness among people across the globe over the harmful effects of this kind of skin disease will further aid in the growth of the acne vulgaris market.

The recent launch of drugs like Galderma’s Epiduo, which efficiently targets acne vulgaris, has further boosted the progress of the market. Several drugs which are under different phases of clinical trials such as AndroScience’s ASC-J9 and Photocure’s Visonac (a type of phototherapy) which will soon be commercialized in the global market, will further provide lucrative growth opportunities to vendors operating in the market. Nevertheless, numerous pharmaceutical companies are unwilling towards investing in the research and development activities owing to the poor return on investment from this sector. This might prove to be a restraint in the growth of the market.

Global Acne Vulgaris Market: Regional Analysis

Geographically, North America accounts for the leading share in the global acne vulgaris market closely trailed by Europe. The key dynamics responsible for the growth of this market in North America are the high prevalence of acne vulgaris along with high awareness and affordability of among people for their treatment.

Global Acne Vulgaris Market: Companies Analyzed in the Report 

Some of the key vendors in the market are AndroScience Corporation, Ausio Pharmaceuticals, LLC, Boehringer Ingelheim GlaxoSmithKline plc, GmbH, Photocure ASA, Galderma S.A., Hygeia Therapeutics, Inc., Quest PharmaTech, Inc., Sol-Gel Technologies Ltd. and Valeant Pharmaceuticals International, Inc.

Acne Vulgaris Market Sees Growth with Advent of Novel Therapeutics

San Francisco, California, May 04, 2017: The report, titled “Acne Vulgaris Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” by TMR Research sheds light on the key developments, market attractiveness, growth drivers, and restraints in the market. The report includes an analysis of the supply chain, apart from a detailed description of the competitive landscape.

One of the most widespread chronic diseases of the sebaceous follicles, acne vulgaris primarily affects the pilosebaceous units in the skin of the face, back, and chest. The skin disorder is characterized by pimples, blackheads or whiteheads, and greasy skin. Due to concerns about their appearance, a number of patients are opting for medical treatments to cure this skin disorder. Combination therapy can treat this condition faster.

Being one of the commonest skin diseases, there are a number of treatments available for acne vulgaris. A wide spectrum of systemic and topical drugs are available in the market, assisting in the advancement of the Acne Vulgaris Market. Some of the most popular therapies recommended for acne vulgaris are combination therapy, topical retinoid, antibiotics, hormonal therapies, and oral isotretinoin. Several dermatologists recommend the use of topical retinoids and benzoyl peroxide. These are available in a variety of formulations such as face washes, gels, creams, and lotions.

High incidence of acne vulgaris, increasing air pollution leading to skin infections, rising awareness about the treatment options available, and the expanding disposable incomes of people are responsible for the steady growth of the global market for acne vulgaris treatments. The recent introduction of advanced drugs such as Galderma’s Epiduo has given an additional impetus to the market. A number of drugs for the treatment of acne vulgaris are in the pipeline. For instance, Photocure’s Visonac, a form of phototherapy, and AndroScience’s ASC-J9 are expected to soon make their appearance in the global market for acne vulgaris. This will further boost the market.

By geography, the global market for acne vulgaris treatments can be segmented into Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America. North America presently leads the global scenario, thanks to the growing prevalence of acne vulgaris and high consciousness pertaining to its treatment. Asia Pacific is expected to display growing demand for acne vulgaris treatment, driven by increasing awareness about this skin disease, vast patient base, and rising number of skin infections across the region. China and India are likely to emerge at the fore, representing a substantial share in the regional market for acne vulgaris treatment.

Galderma S.A., Sol-Gel Technologies Ltd., Boehringer Ingelheim GlaxoSmithKline plc, GmbH, Valeant Pharmaceuticals International, Inc., Photocure ASA, Ausio Pharmaceuticals, LLC, Hygeia Therapeutics, and Quest PharmaTech, Inc. are some of the key players in the global market for acne vulgaris.